Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 355-357

  Yoshimura, Reiji ^a   Kishi, Taro ^b   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Katsuki, Asuka ^a   Umene Nakano, Wakako ^a   Iwata, Nakao ^b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Aripiprazole; Augmentation; Paroxetine; Refractory depression; Sertraline

Indexed keywords

ARIPIPRAZOLE; PAROXETINE; SERTRALINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRESCRIPTION; SCORING SYSTEM; TREATMENT DURATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SERTRALINE;

EID: 84867004841     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.008     Document Type: Article

References (16)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington DC. 4th edn.
2. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:843-853.
3. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Siwanink R., McQuade R.D., et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14:197-206.
4. Crossley N.A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2007, 68:935-940.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
6. Kelsey J.E. Switching drug class after initial SSRI failure. J Clin Psychiatry 1997, 583:26-32.
7. Nelson J.C., Papakostas G.L. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166:980-991.
8. Papakostas G.L. Augmentation strategies in the treatment of major deppresive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr 2007, 12 Suppl 22:10-12.
9. Rush A.J., Trivedi M.H., Winsniewski S.R., Nielenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
10. Seretti A., Cusin C., Lattuada E., Di Bella D., Catalano M., Smeraldi E. Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. Mol Psychiatry 1999, 4:280-283.
11. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel antipsychotic drug with a unique and robust pharmacology. Neuropharmacology 2003, 28:1400-1411.
12. Shinkai K., Yoshimura R., Ueda N., Okamoto K., Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 2004, 24:11-17.
13. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
14. Stahl S.M. Stahl's Essential Psychopharmacology 2008, Cambridge University Press, NY, USA. 3rd ed.
15. Umene-Nakano W., Yoshimura R., Ueda N., Suzuki A., Ikenouchi-Sugita A., Hori H., et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2010, 24:1764-1771.
16. Yoshimura R., Ikenouchi-Sugita A., Hori H., Umene-Nakano W., Katsuki A., Hayashi K., et al. Adding a lowdose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:308-312.